Pediatric ophthalmic conditions: cross-border specialty drug access for international patients

Quick orientation

Pediatric ophthalmic conditions vary widely in prevalence. Common indications for cross-border specialty supply include myopia progression, pediatric uveitis, and rare inherited retinal disease.

Typical age of onset. Childhood and adolescence.

Severity tiers. Severity ranges from refractive errors to vision-threatening conditions.

Why specialty drugs for Pediatric ophthalmic conditions are hard to access internationally

Low-dose atropine for myopia progression, biologics for pediatric uveitis, and gene therapies for inherited retinal disease have differing global access. Cross-border supply addresses gaps where local pharmacy compounding or product registration is limited.

Treatments approved by the FDA

• Vyzulta (latanoprostene bunod, pediatric off-label use varies) — FDA approval: 2017. Mechanism: Nitric oxide-donating prostaglandin analog. Route: Topical ophthalmic. US WAC ballpark: Approximately USD 200 to 400 per month.
• Luxturna (voretigene neparvovec) — FDA approval: 2017. Mechanism: Subretinal gene therapy for RPE65-mediated inherited retinal disease (pediatric label includes 12 months and older). Route: Subretinal injection. US WAC ballpark: Approximately USD 425,000 per eye. Country pricing: UAE · Saudi Arabia · India.
• Vizz (aceclidine ophthalmic solution, adult label) — FDA approval: 2025. Mechanism: Muscarinic agonist (presbyopia label; not a pediatric product but listed for completeness on multi-age ophthalmic context). Route: Topical ophthalmic. US WAC ballpark: Approximately USD 400 to 600 per month. Country pricing: UAE · Saudi Arabia · Lebanon.

Cross-border pathways used for Pediatric ophthalmic conditions

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Personal Import Scheme
• Medical Tourism Access
• Rare Pediatric Disease

What your physician needs to know

• Confirm specific pediatric ophthalmic diagnosis.
• Pediatric ophthalmology specialist co-management is essential.
• Some products require specific age and weight considerations.
• Family training on administration is often required.

Common questions

What pediatric ophthalmic conditions does Reserve Meds support?

We focus on rare and specialty conditions where local supply is limited.

Is Luxturna an option for my child?

Luxturna requires biallelic RPE65 pathogenic variants and is administered at qualified centers. Your retinal specialist assesses eligibility.

Are atropine products available?

Compounded low-dose atropine availability varies; some commercial products are emerging.

How long does shipment take?

Five to fifteen business days for most products.

What documents are required?

Pediatric ophthalmologist's prescription, genetic confirmation where relevant, and clinical summary.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Pediatric ophthalmic conditions, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Pediatric ophthalmic conditions

Reserved for you.